AstraZeneca spinoff scores maiden FDA approval, where it will field Alexion competition and an imminent Roche rival
About a year after the first-ever FDA approval for patients with neuromyelitis optica spectrum disorder (NMOSD), the agency has approved a second therapy for the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
